X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Get Free Report) was the target of unusually large options trading on Friday. Stock traders purchased 2,518 call options on the stock. This represents an increase of approximately 119% compared to the typical daily volume of 1,148 call options.
Insider Activity at X4 Pharmaceuticals
In other X4 Pharmaceuticals news, Chairman Adam R. Craig sold 47,436 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $4.44, for a total value of $210,615.84. Following the completion of the transaction, the chairman directly owned 328,651 shares in the company, valued at $1,459,210.44. This trade represents a 12.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO David Kirske sold 11,767 shares of the business’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $2.86, for a total value of $33,653.62. Following the transaction, the chief financial officer directly owned 155,983 shares in the company, valued at $446,111.38. This trade represents a 7.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 83,779 shares of company stock valued at $353,387. Insiders own 1.13% of the company’s stock.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of XFOR. SummitTX Capital L.P. acquired a new position in shares of X4 Pharmaceuticals in the first quarter valued at approximately $46,000. Pettinga Financial Advisors LLC bought a new position in shares of X4 Pharmaceuticals during the second quarter worth approximately $47,000. WINTON GROUP Ltd increased its stake in shares of X4 Pharmaceuticals by 35.8% during the second quarter. WINTON GROUP Ltd now owns 14,400 shares of the company’s stock worth $67,000 after purchasing an additional 3,800 shares during the period. AXQ Capital LP acquired a new stake in X4 Pharmaceuticals during the 2nd quarter worth approximately $107,000. Finally, Wellington Management Group LLP acquired a new stake in X4 Pharmaceuticals during the 2nd quarter worth approximately $242,000. Institutional investors and hedge funds own 72.03% of the company’s stock.
X4 Pharmaceuticals Price Performance
XFOR stock opened at $3.35 on Friday. The company has a debt-to-equity ratio of 0.49, a current ratio of 11.30 and a quick ratio of 11.02. X4 Pharmaceuticals has a 1-year low of $2.43 and a 1-year high of $4.83. The business’s 50 day simple moving average is $3.33 and its 200 day simple moving average is $3.80.
X4 Pharmaceuticals (NASDAQ:XFOR – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.05. X4 Pharmaceuticals had a negative return on equity of 63.05% and a negative net margin of 568.80%. The business had revenue of $8.81 million during the quarter, compared to the consensus estimate of $2.42 million. As a group, analysts expect that X4 Pharmaceuticals will post -0.67 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of equities analysts recently weighed in on XFOR shares. Weiss Ratings downgraded shares of X4 Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, October 20th. Wells Fargo & Company began coverage on shares of X4 Pharmaceuticals in a research report on Friday, July 10th. They issued an “overweight” rating and a $11.00 price objective for the company. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, X4 Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $11.25.
Get Our Latest Stock Report on XFOR
X4 Pharmaceuticals Company Profile
X4 Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing therapies for rare diseases caused by disorders of the immune system. The company’s research centers on the CXCR4 pathway, which plays a role in the movement and function of immune cells.
X4’s lead product, XOLREMDI (mavorixafor), is an oral CXCR4 antagonist approved by the U.S. Food and Drug Administration for use in patients aged 12 and older with WHIM syndrome, a rare primary immunodeficiency disorder.
Featured Stories
- Five stocks we like better than X4 Pharmaceuticals
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for X4 Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X4 Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
